Drugmaker Lupin acquires anti-diabetes trademarks Gibtulio, Gibtulio Met and Ajaduo from Boehringer Ingelheim International , strengthening its diabetes footprint in the country.

The trademark rights for these brands will be transferred to Lupin by March next year, Lupin said, without giving financial details.

• Read also: Lupin recalls over 6 lakh bottles of hypertension drug in US: USFDA

Lupin has been marketing Gibtulio and Gibtulio Met since 2016 and Ajaduo since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India.

Gibtulio (empagliflozin), Gibtulio Met (empagliflozin + metformin), and Ajaduo (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drugs, that are indicated to improve glycemic control in adults with type 2 diabetes mellitus, along with diet and exercise, the company said.

Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease, the note said.

• Read also: Lupin aims to be part of ‘first wave of generics’ on GLP-1 products: Nilesh Gupta

“Lupin has always been at the forefront of providing best-in-class quality healthcare solutions to patients. This acquisition is a key step in strengthening our diabetes portfolio,” said Nilesh Gupta, Managing Director, Lupin.

Rajeev Sibal, Lupin President – India Region Formulations, added, “The increasing prevalence of diabetes and related lifestyle diseases calls for greater thrust on diabetes treatment and management, as well as accessibility of medicines for patients. This acquisition enables us to deliver effective and affordable treatment options to millions across India.”